Assessing Pim-1 Kinase Inhibition as an Effective Treatment for Acute Myeloid Leukemia
Session Number
MEDH 18
Advisor(s)
Francis Suh, Dr. Hao Wang, Dr. Elizabeth Eklund, Northwestern University, Feinberg School of Medicine, Department of Hematology/Oncology
Discipline
Medical and Health Sciences
Start Date
17-4-2025 2:45 PM
End Date
17-4-2025 3:00 PM
Abstract
Proviral integration site for malignancy-1 (PIM-1) is a serine/threonine kinase proto-oncogene that has many important functions, namely cell proliferation and signal transduction, in the context of Acute Myeloid Leukemia (AML). Generally, PIM-1 kinase, which arises from the expression of the PIM-1 oncogene, can cause poor prognosis of AML. Additionally, PIM-1 kinase, also a substrate of Triad1, stabilizes as expression of Triad1 decreases during the prognosis of AML. Thus, this project looks at PIM-1 kinase inhibition and aims to determine its effectiveness in treatment for AML and how it can affect potential therapeutic interventions. AZD1208, a potent pan-PIM inhibitor, is theorized to be an alternative treatment for AML instead of chemotherapy. This project involves a luciferase reporter assay, which is used to track PIM-1’s gene activation. The assay allows for analyzing PIM-1s impact on signaling pathways and helping determine its oncogenic potential through measuring the fluorescent activity in the Pim-1 kinase promoter.
Assessing Pim-1 Kinase Inhibition as an Effective Treatment for Acute Myeloid Leukemia
Proviral integration site for malignancy-1 (PIM-1) is a serine/threonine kinase proto-oncogene that has many important functions, namely cell proliferation and signal transduction, in the context of Acute Myeloid Leukemia (AML). Generally, PIM-1 kinase, which arises from the expression of the PIM-1 oncogene, can cause poor prognosis of AML. Additionally, PIM-1 kinase, also a substrate of Triad1, stabilizes as expression of Triad1 decreases during the prognosis of AML. Thus, this project looks at PIM-1 kinase inhibition and aims to determine its effectiveness in treatment for AML and how it can affect potential therapeutic interventions. AZD1208, a potent pan-PIM inhibitor, is theorized to be an alternative treatment for AML instead of chemotherapy. This project involves a luciferase reporter assay, which is used to track PIM-1’s gene activation. The assay allows for analyzing PIM-1s impact on signaling pathways and helping determine its oncogenic potential through measuring the fluorescent activity in the Pim-1 kinase promoter.